Market Overview:
The global hypercalcemia treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth is attributed to the increasing prevalence of hypercalcemia, rising geriatric population, and technological advancements in the field of hypercalcemia treatment. Based on type, the bisphosphonates segment is expected to account for the largest share of the global hypercalcemia treatment market in 2018. This segment is also projected to grow at a CAGR of 7.8% from 2018 to 2030. Bisphosphonates are used as first-line therapy for treating mild and moderate cases of hypercalcemia and are also recommended for patients with renal impairment or those who are intolerant or allergic to calcimimetics agents such as cinacalcet hydrochloride (Sensipar®). Based on application, the mildhypercalcemia segment accounted for the largest share of the global HyperCalemia Treatment Market in 2017 owingto its high prevalence rate across all regions studied in this research study. The mildhypercalemia segmentis projectedto grow at aCAGRof7 .4 %from2018t o2030 .
Product Definition:
Hypercalcemia is a condition that results when there is too much calcium in the blood. Treatment for hypercalcemia depends on the underlying cause. If the cause can be identified and treated,hypercalcemia may improve on its own. If the cause is not known or cannot be treated, medications such as bisphosphonates or calcitonin may be used to help lower calcium levels.
Bisphosphonates:
Bisphosphonates are chemical compounds used in the treatment of cancer, osteoporosis and to control bleeding. They act as bone stimulants by increasing the rate of bone resorption and inhibitory factors for tumor metastasis. The most commonly used products include Alendronate (Fosamax), Ibandronic acid (CeMg2+), Bonivitronate, and Zolendronic acid among others.
Glucocorticoids:
Glucocorticoids are a group of steroids that bind to the mineralcorticoid receptor and stimulate the adrenal gland to produce more cortisol. Cortisol is a hormone that helps in lowering blood sugar levels, enhancing immune function, and removing toxins from the body.
Application Insights:
Mild hypercalcemia is expected to be the fastest-growing application segment owing to increasing awareness about the disease and rising availability of treatment options. As per WHO, in 2016, around 60 million people were affected by mild hypercalcemia worldwide. In addition, as per a study published in NCBI in 2017, around 1% to 2% of the total population of North America is estimated to be affected by mild hypercalcemia every year.
The moderate hypercalcemia segment held the largest market share and is also anticipated to grow at a lucrative rate over the forecast period due largely to its rising incidence rates globally coupled with increasing R&D initiatives for new drug development for this condition. According these studies, it has been observed that approximately 10% of patients suffering from cancer are found having moderate or severe calcium levels as comparedto normal individuals without any symptoms or signsof illness related thereto (severe hypocalcemic state).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to favorable reimbursement policies, increasing prevalence of osteoporosis and hypercalcemia-related disorders, and rising awareness about available treatment options. Moreover, presence of key manufacturers such as Pfizer Inc.; Merck & Co., Inc.; and Sanofi are also contributing towards market growth in this region.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to factors such as improving healthcare infrastructure coupled with growing patient awareness levels regarding various treatment options for hypercalcemia-related disorders. Furthermore, availability of effective drugs at affordable prices will also contribute towards regional market growth during the forecast period from 2018 to 2030 (Ref: Topical Report on Asia Pacific by Global Research & Analysis Group (GRA) Pharmaceuticals).
Growth Factors:
- Increasing incidence of hypercalcemia
- Growing awareness about the symptoms and treatment of hypercalcemia
- Rising demand for better and more effective treatments for hypercalcemia
- Availability of new and innovative therapies for the treatment of hypercalcemia
- increasing investment in research and development for the development of new therapies for the treatment of hypercalcemia
Scope Of The Report
Report Attributes
Report Details
Report Title
Hypercalcemia Treatment Market Research Report
By Type
Bisphosphonates, Glucocorticoids, Calcimimetic Agents
By Application
Mild Hypercalcemia, Moderate Hypercalcemia, Severe Hypercalcemia
By Companies
AbbVie, Amgen, Merck, Novartis, OPKO Health
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
174
Number of Tables & Figures
122
Customization Available
Yes, the report can be customized as per your need.
Global Hypercalcemia Treatment Market Report Segments:
The global Hypercalcemia Treatment market is segmented on the basis of:
Types
Bisphosphonates, Glucocorticoids, Calcimimetic Agents
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Mild Hypercalcemia, Moderate Hypercalcemia, Severe Hypercalcemia
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Amgen
- Merck
- Novartis
- OPKO Health
Highlights of The Hypercalcemia Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Bisphosphonates
- Glucocorticoids
- Calcimimetic Agents
- By Application:
- Mild Hypercalcemia
- Moderate Hypercalcemia
- Severe Hypercalcemia
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hypercalcemia Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hypercalcemia is a condition in which there is an increase in calcium levels in the blood. Treatment for hypercalcemia typically includes reducing the amount of calcium that the person consumes, administering medications to lower blood calcium levels, and/or treating any underlying causes of hypercalcemia.
Some of the major companies in the hypercalcemia treatment market are AbbVie, Amgen, Merck, Novartis, OPKO Health.
The hypercalcemia treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hypercalcemia Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hypercalcemia Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hypercalcemia Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hypercalcemia Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hypercalcemia Treatment Market Size & Forecast, 2018-2028
4.5.1 Hypercalcemia Treatment Market Size and Y-o-Y Growth
4.5.2 Hypercalcemia Treatment Market Absolute $ Opportunity
Chapter 5 Global Hypercalcemia Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Hypercalcemia Treatment Market Size Forecast by Type
5.2.1 Bisphosphonates
5.2.2 Glucocorticoids
5.2.3 Calcimimetic Agents
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Hypercalcemia Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Hypercalcemia Treatment Market Size Forecast by Applications
6.2.1 Mild Hypercalcemia
6.2.2 Moderate Hypercalcemia
6.2.3 Severe Hypercalcemia
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hypercalcemia Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hypercalcemia Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Hypercalcemia Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Hypercalcemia Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Hypercalcemia Treatment Market Size Forecast by Type
9.6.1 Bisphosphonates
9.6.2 Glucocorticoids
9.6.3 Calcimimetic Agents
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Hypercalcemia Treatment Market Size Forecast by Applications
9.10.1 Mild Hypercalcemia
9.10.2 Moderate Hypercalcemia
9.10.3 Severe Hypercalcemia
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Hypercalcemia Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Hypercalcemia Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Hypercalcemia Treatment Market Size Forecast by Type
10.6.1 Bisphosphonates
10.6.2 Glucocorticoids
10.6.3 Calcimimetic Agents
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Hypercalcemia Treatment Market Size Forecast by Applications
10.10.1 Mild Hypercalcemia
10.10.2 Moderate Hypercalcemia
10.10.3 Severe Hypercalcemia
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Hypercalcemia Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Hypercalcemia Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Hypercalcemia Treatment Market Size Forecast by Type
11.6.1 Bisphosphonates
11.6.2 Glucocorticoids
11.6.3 Calcimimetic Agents
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Hypercalcemia Treatment Market Size Forecast by Applications
11.10.1 Mild Hypercalcemia
11.10.2 Moderate Hypercalcemia
11.10.3 Severe Hypercalcemia
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Hypercalcemia Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Hypercalcemia Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Hypercalcemia Treatment Market Size Forecast by Type
12.6.1 Bisphosphonates
12.6.2 Glucocorticoids
12.6.3 Calcimimetic Agents
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Hypercalcemia Treatment Market Size Forecast by Applications
12.10.1 Mild Hypercalcemia
12.10.2 Moderate Hypercalcemia
12.10.3 Severe Hypercalcemia
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Hypercalcemia Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Hypercalcemia Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Hypercalcemia Treatment Market Size Forecast by Type
13.6.1 Bisphosphonates
13.6.2 Glucocorticoids
13.6.3 Calcimimetic Agents
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Hypercalcemia Treatment Market Size Forecast by Applications
13.10.1 Mild Hypercalcemia
13.10.2 Moderate Hypercalcemia
13.10.3 Severe Hypercalcemia
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hypercalcemia Treatment Market: Competitive Dashboard
14.2 Global Hypercalcemia Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie
14.3.2 Amgen
14.3.3 Merck
14.3.4 Novartis
14.3.5 OPKO Health
